Brief: Prime Medicine Announces Strategic Restructuring To Focus On Opportunities In Large Genetic Liver Diseases, Cystic Fibrosis, And Partnered Programs Alongside CEO Leadership Transition
19/05/2025 13:35
May 19 (Reuters) - Prime Medicine Inc PRME.O: PRIME MEDICINE ANNOUNCES STRATEGIC RESTRUCTURING TO FOCUS ON OPPORTUNITIES IN LARGE GENETIC LIVER DISEASES, CYSTIC FIBROSIS, AND PARTNERED PROGRAMS ALONGSIDE CEO LEADERSHIP TRANSITION PRIME MEDICINE INC - TO REDUCE HEADCOUNT BY 25% PRIME MEDICINE INC - ALLAN REINE APPOINTED CEO OF PRIME MEDICINE PRIME MEDICINE INC - IN ARBITRATION WITH BEAM THERAPEUTICS OVER AATD PROGRAM PRIME MEDICINE INC: KEITH GOTTESDIENER TO STEP DOWN AS CEO Source text: ID:nGNX6lhsTJ Further company coverage: PRME.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Prime Medicine
See all newsBrief: Prime Medicine Announces U.S. FDA Clearance Of Investigational New Drug Application For Pm647 In Alpha-1 Antitrypsin Deficiency
Prime Medicine, Inc. reports results for the quarter ended June 30 - Earnings Summary
Prime Medicine Q2 net loss narrows on lower expenses
Brief: Prime Medicine, Inc. Q2 EPS USD -0.24
Brief: Prime Medicine Announces U.S. FDA Clearance Of Investigational New Drug Application For Pm577a In H1069q-Mutated Wilson Disease